Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for IPSE.Y from our risk checks.
Ipsen S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €30.64 |
52 Week High | €34.34 |
52 Week Low | €26.97 |
Beta | 0.65 |
11 Month Change | -7.71% |
3 Month Change | 3.24% |
1 Year Change | 4.34% |
33 Year Change | 12.56% |
5 Year Change | -9.59% |
Change since IPO | 69.49% |
Recent News & Updates
Recent updates
Shareholder Returns
IPSE.Y | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -3.8% | 1.0% | 0.5% |
1Y | 4.3% | 17.7% | 23.9% |
Return vs Industry: IPSE.Y underperformed the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: IPSE.Y underperformed the US Market which returned 22.9% over the past year.
Price Volatility
IPSE.Y volatility | |
---|---|
IPSE.Y Average Weekly Movement | 5.8% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IPSE.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: IPSE.Y's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
IPSE.Y fundamental statistics | |
---|---|
Market cap | US$10.06b |
Earnings (TTM) | US$659.86m |
Revenue (TTM) | US$3.54b |
15.2x
P/E Ratio2.8x
P/S RatioIs IPSE.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IPSE.Y income statement (TTM) | |
---|---|
Revenue | €3.31b |
Cost of Revenue | €571.20m |
Gross Profit | €2.74b |
Other Expenses | €2.12b |
Earnings | €617.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 7.47 |
Gross Margin | 82.72% |
Net Profit Margin | 18.66% |
Debt/Equity Ratio | 9.6% |
How did IPSE.Y perform over the long term?
See historical performance and comparison